RESULTS	Arm A : 42 evaluable patients were enrolled with a confirmed RR of 0 % ( 95 % CI 0 % to 8 % ) , median survival of 2.5 months ( 95 % CI 2.0-3 .3 ) , and median time to progression ( TTP ) of 1.2 months ( 95 % CI 1.1 -- 1.3 ) .\